


# TEXTBOOK OF DRUG DESIGN AND DISCOVERY

THIRD EDITION



EDITED BY  
POVL KROGSGAARD-LARSEN  
TOMMY LILJEFORS AND  
ULF MADSEN


---

# Textbook of Drug Design and Discovery

---

Third edition

Povl Krogsgaard-Larsen,  
Tommy Liljefors and  
Ulf Madsen



Y2000122



London and New York



First published 2002  
by Taylor & Francis  
11 New Fetter Lane, London EC4P 4EE

Simultaneously published in the USA and Canada  
by Taylor & Francis Inc,  
29 West 35th Street, New York, NY 10001

*Taylor & Francis is an imprint of the Taylor & Francis Group*

© 2002 Povl Krogsgaard-Larsen

Typeset in Baskerville by  
Integra Software Services Pvt. Ltd, Pondicherry, India  
Printed and bound in Malta by  
Gutenberg Press Ltd.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers.

*British Library Cataloguing in Publication Data*

A catalogue record for this book is available from the British Library

*Library of Congress Cataloging in Publication Data*

A catalog record for this book has been requested

ISBN 0-415-28287-X HB  
ISBN 0-415-28288-8 PB

---

# Contributors

---

**Anderson, Paul S.**

Chemical and Physical  
Sciences R&D  
Bristol-Myers Squibb Company  
P.O. Box 80500  
Wilmington  
DE 19880-0500  
USA

**Andrews, Peter**

Centre for Drug Design and  
Development  
The University of Queensland  
Brisbane  
Queensland 4072  
Australia

**Bang-Andersen, Benny**

H. Lundbeck A/S,  
Department of Medicinal  
Chemistry  
9, Ottiliavej  
DK-2500 Valby  
Denmark

**Bräuner-Osborne, Hans**

Royal Danish School of Pharmacy,  
Department of Medicinal  
Chemistry  
2, Universitetsparken,  
DK-2100 Copenhagen Ø  
Denmark

**Bøgesø, Klaus P.**

H. Lundbeck A/S  
9, Ottiliavej  
DK-2500 Valby  
Denmark

**Copeland, Robert A.**

Chemical Enzymology  
Bristol-Myers Squibb Company  
P.O. Box 80400  
Wilmington  
DE 19880-0400, USA

**De Clercq, Erik**

Rega Institute  
Katholieke Universiteit Leuven  
10, Minderbroedersstraat  
B-3000 Leuven, Belgium

**Dooley, Michael**

Centre for Drug Design  
and Development  
The University of Queensland  
Brisbane  
Queensland 4072  
Australia

**Farver, Ole**

Royal Danish School of Pharmacy  
Department of Analytical and  
Pharmaceutical Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Frydenvang, Karla**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Frølund, Bente**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Hacksell, Uli**

Acadia Pharmaceuticals Inc.  
3911 Sorrento Valley Blvd.  
San Diego  
CA 92121-1402  
USA

**Halldin, Christer**

Department of Clinical NeuroScience  
Psychiatry Section  
Karolinska Hospital  
S-17176 Stockholm  
Sweden

**Herdewijn, Piet**

Rega Institute  
Katholieke Universiteit Leuven  
10, Minderbroedersstraat  
B-3000 Leuven  
Belgium

**Högberg, Thomas**

7TM Pharma A/S  
2, Rønnegade  
DK-2100 Copenhagen  
Denmark

**Jane, David E.**

Department of Pharmacology  
School of Medical Sciences  
University of Bristol  
University Walk  
Bristol BS8 1TD  
UK

**Kastrup, Jette Sandholm**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Kennedy, Ian J.**

Department of Pharmacology  
School of Medical Sciences  
University of Bristol  
University Walk  
Bristol BS8 1TD  
UK

**Krogsgaard-Larsen, Povl**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Larsen, Claus S.**

Royal Danish School of Pharmacy  
Department of Analytical and  
Pharmaceutical Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Larsen, Ingrid Kjøller**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Liljefors, Tommy**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Luthman, Kristina**

Göteborg University  
Department of Chemistry  
Medicinal Chemistry  
S-412 96 Göteborg  
Sweden

**Madsen, Ulf**

Royal Danish School of Pharmacy  
Department of Medicinal Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

**Mitscher, Lester A.**

University of Kansas  
School of Pharmacy  
Department of Medicinal Chemistry  
Lawrence, Kansas 66047-2101  
USA

**Norinder, Ulf**

AstraZeneca R&D  
Discovery  
Medicinal Chemistry  
S-15185 Södertälje  
Sweden

**Pettersson, Ingrid**

Novo Nordisk A/S  
Novo Nordisk Park G8  
DK-2760 Måløv  
Denmark

**Triggle, David J.**

University at Buffalo  
State University of New York  
415 Capen Hall  
Buffalo  
NY 14260-1608  
USA

**Østergaard, Jesper**

Royal Danish School of Pharmacy  
Department of Analytical and  
Pharmaceutical Chemistry  
2, Universitetsparken  
DK-2100 Copenhagen Ø  
Denmark

---

## Preface

---

The field of medicinal chemistry and drug design is in a state of swift development and is at present undergoing major restructuring. The molecular biological revolution and the progressing mapping of the human genome have created a new biochemical and biostructural 'world order'. These developments have provided new challenges and opportunities for drug research in general and for drug design in particular. The major objectives of the medicinal chemists are transformation of pathobiochemical and – physiological data into a 'chemical language' with the aim of designing molecules interacting specifically with the derailed or degenerating processes in the diseased organism.

Potential therapeutic targets are being disclosed with increasing frequency, and this exponential growth will continue during the next decades. In this situation, there is a need for rapid and effective target validation and for accelerated lead discovery procedures. Consequently, most industrial medicinal chemistry laboratories have built up new technologies in order to meet these demands. Key words in this regard are construction of compound libraries, high or ultrahigh throughput screening, accelerated ADME and toxicity tests, and automatized cellular assay systems.

In parallel with this development, biostructure-based drug design and intelligent molecular mimicry or bioisosterism are areas of growing importance in the medicinal chemistry 'playing field'. Structural biology is becoming an increasingly important part of molecular biology and biochemistry, and, furthermore, organic chemists are increasingly directing their attention towards synthetic aspects of biomolecules and biologically active compounds biosynthesized by plants and animals. Thus the borderland between biology, biochemistry, and chemistry is rapidly broadening and is becoming the most fruitful working field for innovative and intuitive drug design scientists.

Where are the academic medicinal chemistry and drug design departments in this area of drug research, which is moving towards an increasing degree of integration of scientific disciplines? Furthermore, how should medicinal chemistry teaching programmes be organized and taught in this highly dynamic research area? These burning questions need to be effectively addressed. In order to attract the attention of intelligent students, the creative and fascinating nature of drug design must be the underlying theme of basic and advanced student courses in medicinal chemistry. In relation to industrial screening programmes and 'hit-finding' procedures, students should be taught that the conversions of 'hits' into



lead structures and further into drug candidates require advanced synthetic chemistry supported by computational chemistry. Furthermore, these medicinal chemistry approaches should be integrated with molecular pharmacology studies using cloned target receptors, ion channels, or enzymes, expressed in appropriate model systems.

It is beyond doubt that a steadily increasing number of biomolecules will be subjected to X-ray crystallographic structural analysis. The number of enzymes with established three-dimensional structure is now increasing exponentially, and this growth will continue during the next decades. Even oligomeric membrane-bound receptors can now be crystallized and subjected to X-ray crystallographic analysis, but such analyses of mono- or oligomeric receptors are still hampered by major experimental difficulties. In recent years, however, biostructural scientists have succeeded in crystallizing recombinant versions of the binding domains of a G protein-coupled receptor as well as a ligand-gated ion channel. Structural analyses of these binding domains co-crystallized with agonist and antagonist ligands have already provided insight into the structural basis of receptor-ligand interactions and of receptor activation and blockade.

These breakthroughs in biostructural chemistry have opened up new avenues in drug design. Structural information derived from X-ray analyses of enzyme-inhibitor conglomerates has been and continues to be very valuable for the design of new types of inhibitors. Similar pieces of information derived from studies of receptor binding domains co-crystallized with different types of competitive or noncompetitive ligands undoubtedly will be of key importance in receptor ligand design projects. These approaches which are in the nature of drug design on a rational basis will become important parts of student teaching programmes in medicinal chemistry.

In academic research and teaching, biologically active natural products probably will play a progressively important role as lead structures. Not only do such compounds often possess novel structural characteristics, but they also frequently exhibit unique biological mechanisms of action, although naturally occurring 'toxins' typically show nonselective pharmacological effects. By systematic structural modification, including molecular mimicry approaches, it has been possible to 'tame' such 'toxins' and convert them into leads with specific actions on biofunctions of key importance in diseases. Biologically active natural products undoubtedly will continue to be important starting points for academic drug design projects, and such approaches will continue to be exciting case stories in student medicinal chemistry courses.

In this third edition of the textbook, all of these aspects of academic and industrial medicinal chemistry and drug design are dealt with in an educational context.

Povl Krogsgaard-Larsen  
Tommy Liljefors  
Ulf Madsen



---

# Contents

---

*List of contributors*

xiv

*Preface*

xvii

1	Drug design and discovery: an overview	1
	LESTER A. MITSCHER	
1.1	Introduction	1
1.2	Historical perspective	2
1.3	What kinds of compounds become drugs?	7
1.4	Preparation and organization for drug seeking	8
1.5	Sources of hits, leads and candidate drugs	11
1.5.1	Natural products	11
1.6	Lead optimization	26
1.7	Cell biology and genomics as a source of drug targets	31
1.8	Future developments	32
	Further reading	33
	References	34
2	Role of molecular recognition in drug design	35
	PETER ANDREWS AND MICHAEL DOOLEY	
2.1	Introduction	35
2.2	Thermodynamic considerations of drug binding	35
2.3	The physical basis of intermolecular interactions	37
2.3.1	Enthalpic contributions	37
2.3.2	Entropic contributions	41
2.4	The total energy of intermolecular interaction	42
2.4.1	Free energy perturbation	42
2.4.2	Partitioning methods	42
2.5	Estimating individual group components in ligand-receptor interactions and co-operativity	43
2.5.1	Intrinsic binding energies	43
2.5.2	Active site mutagenesis	46
2.5.3	'Average' functional group contributions	46
2.5.4	The role of $\Delta G_{t+r}$	47

2.6	<i>Some rules of thumb</i>	49
2.6.1	<i>What should this functional group do for my ligand?</i>	49
2.6.2	<i>How well does my ligand fit the receptor?</i>	50
2.6.3	<i>Conclusion</i>	51
	<i>References and further reading</i>	52
3	<b>Stereochemistry in drug design</b>	54
	IAN J. KENNEDY AND DAVID E. JANE	
3.1	<i>Introduction</i>	54
3.2	<i>What are stereoisomers?</i>	55
3.3	<i>The origin of stereospecificity in molecular recognition</i>	59
3.4	<i>Why is stereochemistry important in drug design?</i>	61
3.4.1	<i>The distomer is inactive (high eudismic ratio)</i>	63
3.4.2	<i>Both enantiomers have independent therapeutic benefits</i>	64
3.4.3	<i>Distomer possesses harmful effects</i>	65
3.4.4	<i>The eutomer and the distomer have the opposite biological activity</i>	65
3.4.5	<i>The racemate has a therapeutic advantage over the individual enantiomers</i>	66
3.4.6	<i>One enantiomer converted into the other in the body</i>	67
3.5	<i>Methods of obtaining pure stereoisomers</i>	67
3.5.1	<i>Resolution of racemates by crystallization of diastereomers</i>	68
3.5.2	<i>Enantioselective chromatography</i>	70
3.5.3	<i>Asymmetric synthesis</i>	74
3.6	<i>Analytical methods of determining purity of stereoisomers</i>	81
3.6.1	<i>Optical rotation</i>	81
3.6.2	<i>NMR spectroscopy</i>	82
3.6.3	<i>Gas chromatography</i>	83
3.6.4	<i>Capillary electrophoresis (CE)</i>	83
3.6.5	<i>Mass spectrometry</i>	84
	<i>Further reading</i>	85
4	<b>Computer-aided development and use of three-dimensional pharmacophore models</b>	86
	TOMMY LILJEFORS AND INGRID PETTERSSON	
4.1	<i>Structure- and pharmacophore-based ligand design</i>	86
4.2	<i>The pharmacophore concept</i>	87
4.3	<i>Basic principles and a step-by-step procedure</i>	88
4.4	<i>Pharmacophore elements and their representations</i>	89
4.4.1	<i>Representation of pharmacophore elements as ligand points and site points</i>	90
4.4.2	<i>Comparison of site-points with experimentally observed ligand-protein interactions</i>	92
4.4.3	<i>Representation of pharmacophore elements by explicit molecular properties</i>	93

4.5	<i>The receptor-bound or 'active' conformation</i>	95
4.5.1	<i>Thermodynamic considerations</i>	95
4.5.2	<i>The conformational energy of the bioactive conformation</i>	97
4.5.3	<i>Conformational analysis</i>	99
4.6	<i>Molecular superimposition</i>	102
4.6.1	<i>Least-squares superimposition, flexible fitting and template forcing</i>	102
4.6.2	<i>The use of molecular superimposition techniques</i>	103
4.7	<i>Receptor-excluded and receptor-essential volumes</i>	103
4.8	<i>Solvation effects</i>	104
4.9	<i>Examples of 3D-pharmacophore models and their use</i>	106
4.9.1	<i>Apomorphine congeners: conformational energies vs. agonist activities</i>	106
4.9.2	<i>A 3D-pharmacophore model for dopamine D<sub>2</sub> receptor antagonists</i>	108
4.9.3	<i>3D-pharmacophore models for the design of selective 5-HT<sub>2A</sub> vs. D<sub>2</sub> receptor antagonists</i>	110
4.9.4	<i>A pharmacophore based database searching for new antimalarial drugs</i>	113
	<i>References</i>	115
	<i>Further reading</i>	115

## 5 Quantitative structure–activity relationships and experimental design

117

ULF NORINDER AND THOMAS HÖGBERG

5.1	<i>Introduction</i>	117
5.2	<i>Hansch analysis</i>	117
5.2.1	<i>Hydrophobic correlations</i>	117
5.2.2	<i>Multifactorial correlations</i>	118
5.3	<i>Physico-chemical properties</i>	120
5.3.1	<i>Electronic descriptors</i>	120
5.3.2	<i>Hydrophobic parameters</i>	120
5.3.3	<i>Steric descriptors</i>	122
5.3.4	<i>Biological relevance</i>	125
5.4	<i>Applications of Hansch equations</i>	125
5.4.1	<i>Hydrophobic and steric factors</i>	125
5.4.2	<i>Influence of electronic and other factors</i>	126
5.4.3	<i>Ionization constants</i>	128
5.4.4	<i>Predictions from equations</i>	128
5.4.5	<i>Blood–brain barrier penetration</i>	130
5.4.6	<i>Relations to molecular modeling</i>	130
5.5	<i>Pattern recognition</i>	131
5.5.1	<i>PCR and PLS methods</i>	131
5.5.2	<i>Application of PLS</i>	134
5.6	<i>3D-QSAR methodologies</i>	135
5.6.1	<i>Methods and strategy</i>	135

5.6.2	<i>Application to steroids</i>	137
5.6.3	<i>Application to dopamine D<sub>1</sub> agonists</i>	141
5.6.4	<i>Application to human rhinovirus</i>	143
5.6.5	<i>Pros and cons</i>	146
5.7	<i>Experimental design</i>	146
5.7.1	<i>Factorial design and principal properties</i>	146
5.7.2	<i>Applications of factorial design</i>	148
5.7.3	<i>Combinatorial chemistry and experimental design</i>	152
	<i>Further reading</i>	153
6	<b>Receptors: structure, function and pharmacology</b>	156
	HANS BRÄUNER-OSBORNE	
6.1	<i>Introduction</i>	156
6.1.1	<i>Synaptic processes and mechanisms</i>	158
6.2	<i>Receptor structure and function</i>	159
6.2.1	<i>G-protein coupled receptors</i>	160
6.2.2	<i>Ligand-gated ion channel receptors</i>	162
6.2.3	<i>Tyrosine kinase receptors</i>	164
6.2.4	<i>Nuclear receptors</i>	166
6.3	<i>Receptor pharmacology</i>	168
6.3.1	<i>Recombinant vs. in situ assays</i>	168
6.3.2	<i>Binding vs. functional assays</i>	168
6.3.3	<i>Partial and full agonists</i>	169
6.3.4	<i>Antagonists</i>	170
6.3.5	<i>Allosteric modulators</i>	171
	<i>Further reading</i>	172
7	<b>Ion channels: structure, function and pharmacology</b>	173
	DAVID J. TRIGGLE	
7.1	<i>Introduction</i>	173
7.1.1	<i>Ion channels and cellular function</i>	173
7.1.2	<i>Ion channels as membrane effectors</i>	173
7.1.3	<i>Ion channels and ion distribution</i>	174
7.1.4	<i>Activation and inactivation of ion channels</i>	177
7.2	<i>Structure and function of ion channels</i>	178
7.2.1	<i>Ion channels as efficient and regulated species</i>	178
7.2.2	<i>The structure of ion channels</i>	179
7.2.3	<i>Families of ion channels</i>	180
7.2.4	<i>Structure–function correlations</i>	182
7.3	<i>The classification of ion channels</i>	183
7.3.1	<i>Criteria for ion channel classification</i>	183
7.3.2	<i>Ion channel classification by electrophysiologic criteria</i>	185
7.3.3	<i>Ion channel classification by drug action</i>	185
7.4	<i>Ion channels as pharmacological receptors</i>	188
7.4.1	<i>Receptor properties of ion channels</i>	188
7.4.2	<i>State-dependent interactions of ion channels</i>	188

---

7.4.3	<i>Structure–activity relationships and state-dependent interactions</i>	191
7.5	<i>Drugs acting at specific ion channels</i>	193
7.5.1	<i>Multiple sites for drug action</i>	193
7.5.2	<i>Drugs acting at Na<sup>+</sup> channels</i>	193
7.5.3	<i>Drugs acting at Ca<sup>2+</sup> channels</i>	196
7.5.4	<i>Drugs acting at K<sup>+</sup> channels</i>	200
7.6	<i>Ion channels and diseases</i>	201
7.7	<i>Ion channels as lethal species</i>	203
7.8	<i>Future developments</i>	203
	<i>Further reading</i>	203
8	<b>Radiotracers: synthesis and use in imaging</b>	205
	CHRISTER HALLDIN AND THOMAS HÖGBERG	
8.1	<i>Introduction</i>	205
8.2	<i>Nuclear chemistry</i>	206
8.3	<i>Long-lived radionuclides</i>	207
8.3.1	<i><sup>14</sup>C-labeled compounds</i>	208
8.3.2	<i><sup>3</sup>H-labeled compounds</i>	209
8.3.3	<i><sup>125</sup>I-labeled compounds</i>	211
8.4	<i>Short-lived radionuclides</i>	213
8.4.1	<i><sup>123</sup>I- and <sup>99m</sup>Tc-labeled compounds</i>	213
8.4.2	<i><sup>76</sup>Br-labeled compounds</i>	215
8.4.3	<i><sup>18</sup>F-labeled compounds</i>	215
8.5	<i>Ultrashort-lived radionuclides</i>	217
8.5.1	<i><sup>11</sup>C-labeled compounds</i>	217
8.5.2	<i><sup>13</sup>N-labeled compounds</i>	222
8.5.3	<i><sup>15</sup>O-labeled compounds</i>	222
8.6	<i>Imaging techniques</i>	223
8.6.1	<i>Autoradiography</i>	223
8.6.2	<i>SPECT</i>	223
8.6.3	<i>PET</i>	224
	<i>Further reading</i>	230
9	<b>Excitatory and inhibitory amino acid receptor ligands</b>	232
	ULF MADSEN AND BENTE FRØLUND	
9.1	<i>Therapeutic prospects for excitatory and inhibitory amino acids</i>	232
9.1.1	<i>Neurodegenerative diseases</i>	232
9.1.2	<i>CNS ischemia</i>	233
9.1.3	<i>Alzheimer's disease</i>	233
9.1.4	<i>Other neurologic disorders</i>	234
9.2	<i>GABA: inhibitory neurotransmitter</i>	235
9.2.1	<i>Therapeutic targets</i>	235
9.2.2	<i>The GABA molecule</i>	236

9.2.3	<i>GABA biosynthesis and metabolism</i>	238
9.2.4	<i>GABA uptake</i>	241
9.2.5	<i>GABA receptors</i>	244
9.3	<i>Glutamic acid: excitatory neurotransmitter and excitotoxin</i>	253
9.3.1	<i>Classification of and ligands for Glu receptors</i>	254
9.3.2	<i>Ibotenic acid: a naturally occurring excitotoxin and lead structure</i>	263
9.4	<i>Future developments</i>	270
	<i>Further reading</i>	271
10	<b>Acetylcholine and histamine receptors and receptor ligands: medicinal chemistry and therapeutic aspects</b>	272
	POVL KROGSGAARD-LARSEN AND KARLA FRYDENVANG	
10.1	<i>Alzheimer's disease</i>	272
10.2	<i>Cholinergic synaptic mechanisms as therapeutic targets</i>	274
10.2.1	<i>Muscarinic and nicotinic acetylcholine receptors and receptor ligands</i>	276
10.2.2	<i>Muscarinic antagonists as pharmacological tools and therapeutic agents</i>	279
10.2.3	<i>Muscarinic agonists and partial agonists: bioisosteric design</i>	282
10.2.4	<i>Muscarinic agonists and partial agonists: synthetic and structural aspects</i>	285
10.2.5	<i>Nicotinic agonists and partial agonists: bioisosteric design</i>	288
10.2.6	<i>Nicotinic agonists: synthetic aspects</i>	289
10.2.7	<i>Acetylcholinesterase inhibitors</i>	290
10.3	<i>Histamine receptors</i>	292
10.3.1	<i>Protolytic properties of histamine and histamine analogs</i>	294
10.3.2	<i>H<sub>2</sub> and H<sub>3</sub> receptor antagonists: design and therapeutic aspects</i>	294
	<i>Further reading</i>	297
11	<b>Dopamine and serotonin receptor and transporter ligands</b>	299
	KLAUS P. BØGESØ AND BENNY BANG-ANDERSEN	
11.1	<i>Receptors and transporters for dopamine and serotonin</i>	299
11.2	<i>Dopamine and serotonin receptor ligands</i>	300
11.2.1	<i>Molecular biology and structure of receptors for dopamine and serotonin</i>	300
11.2.2	<i>Antipsychotic drugs</i>	302
11.3	<i>Dopamine and serotonin transporter ligands</i>	312
11.3.1	<i>Molecular biology and structure of transporters for biogenic amines</i>	312

---

11.3.2 Antidepressant drugs	314
11.3.3 Dopamine uptake inhibitors	323
Further reading	326
12 Enzymes and enzyme inhibitors	328
ROBERT A. COPELAND AND PAUL S. ANDERSON	
12.1 Introduction	328
12.2 Chemical mechanisms of enzyme catalysis	329
12.2.1 Transition-state theory in enzyme catalysis	330
12.2.2 Active site structure stabilizes the transition state	335
12.2.3 Strategies for transition-state stabilization	336
12.3 Reversible enzyme inhibitors	342
12.3.1 Competitive inhibition	342
12.3.2 Non-competitive inhibition	350
12.3.3 Uncompetitive inhibition	354
12.4 Other types of inhibitors	356
12.4.1 Slow, tight-binding inhibitors	356
12.4.2 Covalent enzyme modifiers	358
12.4.3 Mechanism-based enzyme inhibitors	360
12.5 Summary	361
Further reading	362
13 Metals in medicine: inorganic medicinal chemistry	364
OLE FARVER	
13.1 Introduction	364
13.1.1 Essential and non-essential elements	365
13.1.2 History	366
13.2 Classification of inorganic pharmaceuticals	367
13.3 The human body and bioinorganic chemistry	368
13.4 Co-ordination chemistry	371
13.4.1 Chelate effect	371
13.4.2 Hard and soft acids and bases (HSAB principle)	373
13.4.3 Kinetics: inert and labile complexes	374
13.4.4 Redox reactions	377
13.4.5 The trans-effect	378
13.4.6 Plasma mobilization index	380
13.5 Chelate therapy	382
13.5.1 Synergistic chelate therapy	382
13.6 Selected chelates	383
13.6.1 BAL	383
13.6.2 D-penicillamine	383
13.6.3 EDTA	383
13.6.4 Desferrioxamine	385
13.7 Drug-metal ion interaction	385
13.7.1 Undesirable interactions	386
13.7.2 Beneficial interactions	386



13.8	<i>Inorganic chemistry and pharmaceuticals</i>	386
13.8.1	<i>Alkali metals</i>	387
13.8.2	<i>Alkaline earth metals</i>	389
13.8.3	<i>The chromium group</i>	391
13.8.4	<i>Iron and cobalt</i>	392
13.8.5	<i>Platinum and ruthenium</i>	398
13.8.6	<i>Copper, silver, and gold</i>	399
13.8.7	<i>Zinc, cadmium, and mercury</i>	404
13.8.8	<i>Antimony and bismuth</i>	407
13.9	<i>Concluding remarks</i>	408
	<i>Further reading</i>	409
14	<b>Design and application of prodrugs</b>	410
	CLAUS S. LARSEN AND JESPER ØSTERGAARD	
14.1	<i>The prodrug concept</i>	410
14.1.1	<i>Definition</i>	410
14.1.2	<i>Barriers to drug action</i>	411
14.1.3	<i>Prodrug design in an industrial setting</i>	412
14.2	<i>Choice and function of the pro-moiety</i>	413
14.2.1	<i>Cleavability of the prodrug bond</i>	414
14.2.2	<i>Modification of physicochemical properties</i>	417
14.2.3	<i>Macromolecular transport vectors</i>	423
14.3	<i>Bioreversible derivatives for various functional groups</i>	426
14.3.1	<i>Esters as prodrugs for compounds containing carboxyl or hydroxy groups</i>	428
14.3.2	<i>Prodrugs for amides, imides and other NH-acidic compounds</i>	430
14.3.3	<i>Prodrugs for amines</i>	435
14.3.4	<i>Prodrugs for compounds containing carbonyl groups</i>	437
14.3.5	<i>Drug activation from intramolecular cyclization reactions</i>	438
14.3.6	<i>Cyclic prodrugs involving two functional groups of the drug</i>	442
14.4	<i>Applications of the prodrug approach</i>	444
14.4.1	<i>Biomembrane passage and bioavailability</i>	444
14.4.2	<i>Site-specific drug delivery</i>	451
14.4.3	<i>Improvement of drug formulation</i>	454
	<i>Further reading</i>	458
15	<b>Peptides and peptidomimetics</b>	459
	KRISTINA LUTHMAN AND ULI HACKSELL	
15.1	<i>Introduction</i>	459
15.1.1	<i>Peptide structure</i>	459
15.1.2	<i>Solid phase peptide synthesis</i>	460

15.1.3	<i>Biosynthesis of peptides</i>	461
15.1.4	<i>Peptide-G-protein coupled receptor interactions</i>	463
15.2	<i>Strategies for peptidomimetic drug discovery</i>	465
15.2.1	<i>Design of peptidomimetics</i>	466
15.2.2	<i>Discovery of peptidomimetics using receptor/enzyme-based screening</i>	473
	<i>Further reading</i>	481
16	<b>Classical antiviral agents and design of new antiviral agents</b>	486
	PIET HERDEWIJN AND ERIK DE CLERCQ	
16.1	<i>Classical antiviral agents</i>	486
16.1.1	<i>Introduction</i>	486
16.1.2	<i>Base-modified pyrimidine nucleosides as antiherpes agents</i>	488
16.1.3	<i>Sugar-modified purine nucleosides</i>	491
16.1.4	<i>Ribavirin</i>	493
16.1.5	<i>Compounds which inhibit the replication of the human immunodeficiency virus (HIV)</i>	494
16.2	<i>Design of new antiviral agents</i>	500
16.2.1	<i>Nucleoside prodrugs</i>	500
16.2.2	<i>Analogs of 5'-monophosphates and nucleotide prodrugs</i>	501
16.2.3	<i>Nucleosides with the non-natural L-configuration</i>	504
16.2.4	<i>Non-nucleoside antivirals outside the anti-HIV field</i>	504
16.2.5	<i>New developments in the anti-HIV-field</i>	507
	<i>Further reading</i>	510
17	<b>Anticancer agents</b>	511
	INGRID KJØLLER LARSEN AND JETTE SANDHOLM KASTRUP	
17.1	<i>DNA as target for anticancer drugs</i>	511
17.1.1	<i>Drugs interacting directly with DNA</i>	512
17.1.2	<i>Drugs interfering with DNA synthesis</i>	537
17.2	<i>Mitotic apparatus as target for drugs</i>	550
17.2.1	<i>Drugs interfering with the Vinca alkaloid binding site of tubulin</i>	550
17.2.2	<i>Drugs interfering with the colchicine binding site of tubulin</i>	553
17.2.3	<i>Drugs stabilizing the assembly of tubulin into microtubules</i>	554
	<i>Further reading</i>	556
	<i>Index</i>	559